Showing results (41-50 of 65) with videos related to
Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2017
Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder CancerGillian Vandekerkhove, Tilman Todenhöfer, Matti Annala, et al.Cancer Discovery|January 26, 2018
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerMatti Annala, Gillian Vandekerkhove, Daniel Khalaf, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2019
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate CancerElie Ritch, Simon Y F Fu, Cameron Herberts, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2023
Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate CancerSofie H Tolmeijer, Emmy Boerrigter, Takayuki Sumiyoshi, et al.European Urology|January 15, 2019
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate CancerGillian Vandekerkhove, Werner J Struss, Matti Annala, et al.Nature Communications|January 9, 2021
Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancerGillian Vandekerkhove, Jean-Michel Lavoie, Matti Annala, et al.The Lancet. Oncology|November 16, 2019
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trialDaniel J Khalaf, Matti Annala, Sinja Taavitsainen, et al.Journal of the National Cancer Institute|December 6, 2017
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate CancerAlexander W Wyatt, Matti Annala, Rahul Aggarwal, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway InhibitionMatti Annala, Sinja Taavitsainen, Daniel J Khalaf, et al.Nature Genetics|January 7, 2014
A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin bindingQilai Huang, Thomas Whitington, Ping Gao, et al.Pageof 7